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Abstract 
Aims:&We investigate mucosal addressin cell-adhesion molecule (MAdCAM)-1 as a reliable target to detect 
active bowel inflammation for selective non-invasive nanodiagnostics. 
Materials and Methods: We coupled anti-MAdCAM-1 antibodies to manganese oxide nanoparticles, and 
analyzed nanoconjugate biodistribution and safety in murine model of inflammatory bowel disease by 
imaging and histology.  
Results: Nanoparticles were stable and non-toxic. Upon administration in colitic mice, anti-MAdCAM-1-
functionalized nanoparticles preferentially localized in the inflamed bowel, whereas untargeted nanoparticles 
were more rapidly washed out. Nanoparticles did not induce lesions in non-target organs. 
Conclusions: Anti-MAdCAM-1-functionalized nanoparticles detected active bowel inflammation foci, 
accurately following MAdCAM-1 expression pattern. These nanoconjugates could be a promising non-
invasive imaging system for an early and accurate follow-up in patients affected by acute colitis. 
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Introduction 
In recent years, a global rising of incidence of inflammatory bowel diseases (IBD) has been observed.[1-3] 
The European Crohn’s and Colitis Organization (ECCO) stated that clinical stadiation and follow-up of IBD 
includes ileo-colonoscopy with biopsies to assess the presence and the severity of the disease.[4] Endoscopy 
allows clinicians to exclude recurrence and to verify mucosal healing after therapy; moreover, accuracy of 
ileo-colonoscopy is significantly higher than imaging for terminal ileum diagnostics, especially for mild 
lesions.[5] Therefore, millions of people worldwide annually undergo invasive procedures for proper follow-
up of their disease, with a negative impact on quality of life and a major psychological burden.[6,7] In the 
emergency setting, acute severe colitis requiring urgent colectomy could be avoided in some cases by an 
early recognition of increased severity of IBD, leading to a proper therapy escalation [8]. In other cases, the 
early recognition of therapy failure could lead to prompt urgent colectomy, thus avoiding higher 
complications rate and mortality, which are often described with delayed surgery for misdiagnosed refractory 
colitis [9]. This fact is particularly relevant in paediatric ulcerative colitis, since an accurate and early 
assessment or therapy response predicts the clinical course of the disease and the need of medical salvage 
therapy [10]. Evaluation of acute colitis in IBD could be completed by computed tomography (CT) scan or 
ultrasound [4]. However these techniques rely on aspecific radiological signs of bowel inflammation, such as 
contrast enhancement of bowel wall thickening, and specific targeted imaging is still lacking.[11] 
Consequently the current best clinical management for IBD evaluation only offers an approximation of the 
real clinical scenario, and an accurate stadiation of IBD for assessment of response to therapies or indication 
for surgery is challenging. 
Mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) has been proposed as a marker of bowel 
inflammation. It is upregulated on gut endothelium in IBD at very early stages of the disease, and is 
responsible for recruiting T cells by binding the integrin α4β7, with subsequent promotion of chronic 
inflammation in involved bowel tracts.[12,13] Interestingly, MAdCAM-1 is also finely related to IBD onset 
and activity, and plays a role in the response to therapy, since its expression is higher in non-responder 
patients and decreases in case of remission after anti-TNFα treatment.[14] In recent years, it is emerging that 
targeting leukocyte homing is a successful strategy for induction and maintenance of remission in IBD, and 
open new concept in IBD management.[15-18]  
Here, MAdCAM-1 was investigated as a reliable and early IBD-related endothelial target to be exploited for 
site-specific nanotheranostics in a murine model of acute bowel inflammation.  Indeed, oral administration of 
dextran sodium sulfate (DSS) for a short period of time is widely used in preclinical research to induce 
reproducible colitis in mice.[19] This model reproduces some morphological features of human colitis, 
including leukocytes infiltration, increased production of proinflammatory factors, and over-expression of 
adhesion molecules. Moreover, it has been demonstrated that ablation or inhibition of MAdCAM-1 
ameliorates colitis in DSS-induced IBD.[20,21] From these concerns, we reasoned that DSS-induced acute 
bowel inflammation could have been suitable to investigate MAdCAM-1 as an early and IBD-related 
molecular target. Anti-MAdCAM-1 antibody was conjugated to a smart and safe delivery nanoparticle, 
consisting of a manganese oxide core coated with an amphiphilic polymer. This nanoparticle could hold 
multifunctional properties, deriving from both the magnetic property of the core and the surface 
functionalization, to implement imaging and targeted drug delivery. Nanomedicine offers exclusive 
opportunities to design novel imaging agents and targeted therapeutic carriers, thanks to tunable properties of 
nanomaterials, which make them particularly appreciable for several biomedical applications.[22] In 
particular, nuclear spin-active metal nanocrystals, including iron(II,III), Mn(II) and Gd(III) oxides, exhibit 
unique paramagnetic properties that make them suitable as powerful contrast enhancers in MRI. While 
superparamagnetic iron oxide nanoparticles (Fe3O4 and γ-Fe2O3) are extensively utilized as contrast agents in 
T2-weighted images,[23,24] MnO and Gd2O3 nanoparticles can be exploited for positive contrast in T1-
weighted imaging, leading to bright signal in correspondence to nanoparticle accumulation in specific tissue 
areas.[25,26] This effect could be of great utility for imaging of the bowel, which provides intrinsically dark 
MRI in absence of contrast enhancers.  
The aim of this study was to assess the targeting efficacy and the accuracy of innovative low-toxic MnO 
nanoparticles functionalized with anti-MAdCAM-1 antibodies, specifically designed to detect active bowel 
inflammation foci at early stages of the disease. Pursuing this targeted strategy has the potential to provide a 
non-invasive and specific system to improve clinical care and management of IBD patients. 
!  
Materials and Methods   
Synthesis of MnO nanoparticles 
The synthesis of MnO nanoparticles (MnO NPs) was carried out according to a two-steps protocol 
previously described,[25] consisting of the synthesis of the precursor from a metal salt and its subsequent 
solvothermal decomposition (see Supplementary Information for details). Phase transfer from chloroform to 
water solution was achieved by coating the nanoparticles with a modified poly(isobutylene-alt-maleic 
anhydride) (PMA), according to a previously reported procedure.[27,28] Then, the suspension was dried and 
further redispersed in sodium borate buffer (3 mL) at pH 12 by sonication. Nanoparticles were three times 
washed and centrifuged (811 ×g, 10 min, Scanspeed 173OR, Labogene), purified by gel electrophoresis as 
described elsewhere,[29] and finally resuspended in deionized water at a stock concentration (MnO-PMA 
NPs). 
 
Nanoparticles characterization 
Nanoparticle hydrodynamic size was determined by dynamic light scattering (DLS) using a Malvern® 90 
Plus DLS instrument (15 mW solid state laser). Backscattered light at a fixed scattering angle of 173° was 
collected to provide the scattering signal. MnO and MnO-PMA NPs samples were prepared by diluting the 
stock solution in a disposable cuvette with 1 cm optical length in ultrapure water to 50 µg mL–1 and allowed 
to equilibrate at 25 °C for 30 s before analysis. Mean hydrodynamic diameter and standard deviation were 
calculated with multimodal analysis by Mie theory, considering absolute viscosity and refractive index 
values of the medium to be 0.911 cP and 1.330 for water and 0.542 cP and 1.446 for chloroform, 
respectively. Three replicate measurements per sample were performed to establish the measurements 
reliability. ζ-potential was determined with the same instrument equipped with DTS1070 electrode and data 
were processed by ZetaPlus Software. ζ-potential was calculated from electrophoretic mobility based on 
Smoluchowski equation. A viscosity of 0.911 cP, a dielectric constant of 78.5, and Henry function of 1.5 
were used for the calculations. The results were expressed as mean ± standard deviation (SD) of three 
measurements.  Transmission electron microscopy (TEM) images were obtained with a Zeiss EM-109 
microscope operating at 80 kV. The sample (2 µL, 0.1 µg mL–1) was deposited onto a 200-mesh 
formvar/carbon-coated copper grid (Ted Pella, Redding, CA, USA), and air-dried before examination. The 
particle size distribution and the average particle size were calculated measuring at least 200 particles by a 
Measure IT Olympus Software.  
 
Surface functionalization with antibodies 
MnO-PMA NPs were functionalized with the half-chain of a monoclonal anti-MAdCAM-1 antibody (AP-
MAB0842, Abcam) (MnO-MdC) or with a nonspecific anti-rabbit IgG molecule (Sigma-Aldrich) (MnO-
IgG). To obtain fluorescent molecules for optical visualization, antibodies were first labeled with the organic 
dye fluorescein isothiocyanate (FITC),[30] and dissolved in EDTA-PBS (1 mg mL–1). Subsequently, 
antibodies were added to 2-mercaptoethanolamine kit (MEA, Thermo Scientific) and treated according to the 
manufacturer’s protocol to reduce the disulfide bridges between the two heavy chains. Half-chain 
quantification was performed by UV-vis analysis at 280 nm wavelength. A 2,2-
(ethylenedioxy)bis(ethylamine) aqueous solution (EDBE, 0.05 M, 9 µL) was added to MnO-PMA NPs that 
were further modified with N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP, 690 µL, 10 mg mL–1) in 
dimethylsulfoxide, following a previously-established procedure.[30] The resulting thiol-reactive MnO-PMA 
NPs (1 mg) were incubated at room temperature (RT) for 1 h with 100 µg half-chain antibody (50 µl, 2 mg 
mL-1). It was estimated an average of 4-5 MdC per nanoparticle, calculated by the UV-visible absorption 
value of pyridine-2-thione (λ = 343 nm, ε = 8.08*10^+3 M-1 cm-1) that detached from SPDP molecule during 
the MdC antibody conjugation. Eventually, a molar excess of polyethylene glycol (PEG-SH, Mw=500 Da, 
100 µg, 10 µl, 10 mg mL-1) was linked covalently to the surface of the NPs to saturate the remaining thiol-
reactive functional groups. The excess of reagents was removed by dialysis. 
 
In vitro cytotoxicity studies  
SVEC4-10 murine endothelial cell line was purchased by ATCC-LGC Standards (Sesto San Giovanni, IT) 
and cultured in high glucose Dulbecco’s modified Eagle medium (Euroclone S.p.A., Milano, IT) 
supplemented with 10% heat inactivated fetal bovine serum (Euroclone), 2 mM L-glutamine, 100 U mL–1 
penicillin, 0.1 mg mL–1 streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. At 
confluence, the cells were passaged using trypsin-EDTA (Euroclone). For the cell proliferation assay, cells 
(5×103) were seeded onto 96-well tissue culture plates and incubated with different amounts of MnO-PMA 
NPs dissolved in the culture medium. At 24, 48 and 72 h, cells were washed with phosphate buffer saline 
(PBS) and tested with CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega Italia s.r.l., 
Milano, IT), according to the manufacturer’s instructions. Absorbance was read using a testing wavelength 
of 490 nm and a reference wavelength of 630 nm. For the apoptosis assay, cells were seeded onto 12-well 
tissue culture plates, incubated with different amounts of MnO-PMA NPs for 4 or 24 h at 37 °C, washed 
twice with PBS and treated with the Annexin V-PE-Cy5 Apoptosis Detection Kit (BioVision, Milpitas, US-
CA) following the manufacturer’s protocol. Cells were analyzed on a FACS Calibur flow cytometer (Becton 
Dickinson). After gating on viable cells, 10,000 events were acquired for each analysis.  
 
Hemolysis assay 
Blood samples from healthy volunteers were freshly collected and centrifuged at 690 ×g for 5 min to isolate 
packed erythrocytes from the plasma. The pellet was washed three times with sterile PBS 1x (pH 7.4) until 
supernatant was clear, and finally resuspended 1:10 in sterile PBS. Cell suspension (200 µL) was mixed with 
800 µL of MnO-MdC or MnO-IgG NPs suspension at different concentrations (0.005, 0.02 and 0.1 mg mL–1 
in PBS), gently vortexed and incubated at 37 °C for 30 min, 2 h and 24 h. Double-distilled water and PBS 1x 
were used as the positive and negative control, respectively. After incubation, samples were centrifuged at 
690 ×g for 5 min, and the release of hemoglobin was measured on 100 µL of supernatant by a microplate 
reader ELx800 (Biotek, Milano, IT) using a testing wavelength of 405 nm. The percentage of hemolysis was 
calculated as follows: (Abssample – AbsCTRL-)*100/(AbsCTRL+ – AbsCTRL-). Analysis was performed in triplicate. 
 
Experimental model of colitis  
Male C57BL/6 mice (8 weeks old) were purchased from Charles River (Calco, IT), group housed (4 
mice/cage) under standard laboratory conditions, and allowed to acclimate for 1 week. Colitis was induced 
by addition of dextran sulfate sodium salt (DSS, 3% w/v, 40 kDa, MP Biomedicals, Santa Ana, US-CA) to 
the drinking water, by changing beverage each 2 days. Colitis was monitored daily, by scoring standard 
parameters of body weight change, stool consistency and fecal blood, which were summed together to 
calculate the disease activity index (DAI), as previously described (see Supplementary Information for 
details).[31,32] After 3, 5 and 7 days of treatment, colon length was measured ex vivo with a ruler from the 
ileum/colon boundary down to the rectum. Dissected bowels were washed with PBS by gentle flushing, and 
either fixed in 10% formalin for histologic assessment or subdivided into proximal and distal part of colon, 
snap frozen and used for protein extraction.  
 
Protein extraction and western blotting 
Frozen tissues were weighted, homogenized with potter (Glas-Col homogenizer) in 20% w/v Triton lysis 
buffer (20 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 10% Glycerol and 1% Triton X-100), 
containing 4% Protease Inhibitor Cocktail (Sigma-Aldrich S.r.l., Milan, IT), and cleared at 17,100 ×g for 20 
min at 4 °C. A 40 µg aliquot of protein was resuspended in Laemmli buffer, resolved on polyacrylamide gels 
under reducing conditions and transferred to polyvinylidene difluoride membranes (Immobilon-P, EMD 
Millipore Corporation, Billerica, MA-US). Membranes were blocked with 5% bovine serum albumin (BSA, 
Sigma-Aldrich) in Tris buffer saline with 0.1 % Tween-20 (Sigma-Aldrich) for 1 h at RT, and incubated with 
rat anti-MAdCAM-1 antibody (MECA-367, LifeSpan BioSciences, Seattle, WA) or with rabbit anti-GAPDH 
(Sigma-Aldrich). Antibodies conjugated to horseradish peroxidase (Abcam) were used as secondary 
antibodies, and the reaction was developed with the ECL star kit (Euroclone). Densitometric analysis of 
protein bands was performed with ImageJ software. 
 
Nanoparticles administration and biodistribution analysis 
Nanoparticles were administered to mice (n=36) previously treated with DSS for 5 days. The injection was 
performed in the tail vein upon anesthesia by intraperitoneal injection of avertin (250 µg g–1 body weight). 
Colitic mice were randomly treated with fluorescent-labeled MnO-MdC (n=16) or MnO-IgG (n=16) (5 µg 
MnO/g body weight). Control colitic mice (n=4) were injected with 0.1 mL sterile saline solution, and used 
as reference for tissue autofluorescence. At 4 and 24 h post-injection, 8 mice per group were euthanized for 
analysis of nanoparticle biodistribution and systemic toxicity. Bowel, heart, spleen, lungs, kidneys, liver 
were dissected from mice, washed with PBS, wiped, and either analyzed in a IVIS Lumina II imaging system 
(Calipers Life Sciences, UK) (n=5) or fixed in 10% formalin for histologic assessment (n=3). IVIS images 
were acquired with a green fluorescent protein emission filter, while excitation was scanned from 430 to 500 
nm, and fluorescence was corrected by spectral unmixing for each sample. Epifluorescence intensity was 
measured in the entire colon of nanoparticles-treated mice, and average autofluorescence measured in the 
colon of saline-injected mice was subtracted. For normalization of bowel epifluorescence, blood was 
collected from the retro-orbital plexus of anesthetized mice before euthanasia, and collected in EDTA-coated 
tubes (Becton Dickinson). Plasma was prepared by centrifugation at 1500 ×g for 15 min at 4 °C and 
analyzed by spectrofluorimetric analysis (Horiba; λex = 480 nm; λem = 520 nm). Background plasma 
fluorescence, determined in samples from saline-injected mice, was subtracted from each sample. 
Normalized colon epifluorescence was then calculated as the ratio between average epifluorescence of the 
colon and fluorescence intensity measured in the plasma of the same animal. 
 
Histologic assessment 
Bowel, liver, kidneys, spleen, heart and lung samples were fixed with 10% buffered formalin for at least 48 h 
at RT and embedded in paraffin. Three µm sections were cut, stained with haematoxylin and eosin (HE) and 
examined blindly. 
 
Immunohistochemistry 
Three µm paraffin sections were cut, dewaxed in xylene and rehydrated in alcohol. Antigen unmasking was 
performed in microwave oven (citrate buffer pH 6) for 10 min. Endogenous peroxidase and unspecific 
binding sites were blocked by using appropriate reagents. Sections were incubated with affinity-purified anti-
MAdCAM1 antibody for 2 h at RT in a humid chamber. The reaction was revealed by nonbiotin peroxidase 
detection system with 3,3'-diaminobenzidine free base (DAB) as chromogen (haematoxylin counterstaining). 
The omission of primary antibody was used as negative control. 
 
Transmission electron microscopy 
Small pieces of proximal and distal colon (n=2) were fixed in 2.5% glutaraldehyde (Electron Microscopy 
Sciences) in 0.1 M phosphate buffer, pH 7.2, for 2 h. Specimens were rinsed with phosphate buffer, and 
post-fixed in 1.5% osmium tetroxide (Electron Microscopy Sciences) for 2 h, dehydrated by 70, 90 and 
100% EtOH, and embedded in epoxy resin (PolyBed 812 Polysciences Inc). Ultrathin sections were 
examined by TEM (Zeiss EM109). 
 
Statistical analysis 
Statistical analyses were conducted using two-tailed Student’s t-test. All plots show mean ± standard error 
(SE). The statistical significance threshold was set at P < 0.05. 
 
Study approval 
Animal care was in accordance with institution guidelines. The experimental protocol of the study was 
subjected to the direct approval of the Italian Ministry of Health.   
Results    
Preparation and characterization of nanoparticles 
MnO and MnO-PMA NPs were prepared and stored as stock solutions in chloroform and water, respectively. 
Hydrodynamic diameter (d), polydispersity index (PdI), and ζ-potential values of NPs are shown in Table 1. 
MnO and MnO-PMA NPs showed a hydrodynamic diameter of 15.0 nm ± 0.3 nm and 41.1 nm ± 1.9 nm, 
respectively. MnO-PMA NPs were negatively charged (-44.7 mV ± 0.6 mV). Micrographs of MnO NPs are 
shown in Figure 1. Size distribution analyses calculated from 200 particles confirmed that NPs were 
monodispersed. 
 
In vitro biocompatibility of nanoparticles 
Cell toxicity effect was investigated by incubating 5, 20 or 100 µg mL–1 of MnO-PMA NPs on murine 
endothelial cells, and assessing cell viability at different time (Figure 2A). MnO-PMA NPs were safe, with 
only a mild reduction in cell viability at the highest tested dose (19.48 % ± 3.15 reduction, unvaried in time). 
Apoptosis was investigated after 4 and 24 h of incubation, with no significant difference between control and 
MnO-PMA NPs-treated cells (Figure 2B). Potential harmful effects of nanoparticles were also analyzed by 
hemolysis assay on blood samples incubated with increasing concentrations of MnO-MdC or MnO-IgG 
nanoparticles. Negligible effect (less than 2 % hemolysis) was observed even after 24 h incubation with 100 
µg mL–1 of nanoparticles (Figure 2C). Taken together, these in vitro results indicated a good safety profile 
for MnO-PMA NPs and suitability for intravenous injection.  
 
MAdCAM-1 expression in IBD experimental model 
Aim at testing MnO-PMA NPs in vivo, we reproduced a murine acute colitis model by treating mice with 3% 
DSS over 7 days. DSS treatment progressively induced loss of body weight, diarrhea and rectal bleeding, 
which were scored daily as clinical parameters associated with active colitis (Figure 3A, B, C). The disease 
activity index (DAI) revealed an acute phase of bowel inflammation starting at 5 days of treatment (Figure 
3D). Bowel damage was first assessed by measuring colon length ex vivo. Colon was only slightly reduced 
after 3 days of treatment, while it drastically shortened by 33.7% and 35.9% after 5 and 7 days, respectively 
(Figure 3E). Colon damage was confirmed by histological analysis on bowel tissues: inflammation and 
ulceration were observed at 5 and 7 days with loss of the epithelial lining of mucosa surface and glands 
(Figure 3F). No inflammation was demonstrated in control and 3-days-treated mice. 
MAdCAM-1 expression profile was analyzed by western blotting on bowel tissue homogenates (Figure 4A, 
B). DSS induced over-expression of MAdCAM-1 in both proximal and distal colon at 5 and 7 days of 
treatment (Figure 4B). Interestingly, MAdCAM-1 over-expression was initially higher in the proximal part 
of the colon than in the distal one (P=0.013). Immunohistochemistry on bowel tissue slides confirmed the 
increase in MAdCAM-1 upon DSS treatment: very few vessels were stained positive in control and 3-days-
treated mice, while MAdCAM-1 staining dramatically increased in mucosal vascular endothelium in the 
areas of damage after 5 and 7 days (Figure 4C). MAdCAM-1 expression pattern correlated with the 
histologic assessment of inflammatory lesions (Supplementary Figure 1).  
 
Nano-targeting of the inflamed colon 
We first confirmed the targeting capability of MnO-MdC nanoconjugates by in vitro immunoprecipitation 
assay with a purified recombinant murine MAdCAM-1 protein. Results showed effective recognition of the 
target protein by MnO-MdC NPs, while untargeted MnO-IgG or MnO-PMA did not manage to significantly 
pull-down MAdCAM-1 protein (see Supplementary Figure 2). Then, fluorescently-labeled MnO-MdC NPs 
or equal amount of untargeted MnO-IgG NPs were injected into the tail vein of mice treated with DSS for 5 
days. At 4 and 24 h post-injection, dissected bowels were analyzed. The injection of either MnO-MdC or 
MnO-IgG NPs did not impact on the length of colon in DSS-treated mice, which appeared shorter than that 
of healthy mice (Figure 5A). At 4 h post-injection nanoparticles localized in the bowel of colitic mice, and 
comparable fluorescence intensity was measured in MnO-MdC- and MnO-IgG-treated bowels. At 24 h post-
injection MnO-MdC NPs further accumulated in the bowels of mice, as shown by increased fluorescence as 
compared to MnO-IgG-treated bowels (Figure 5B, D). Bowel-associated epifluorescence was normalized 
toward fluorescence measured in the blood of the same mice before euthanasia, and results confirmed the 
specific localization of MnO-MdC NPs versus MnO-IgG NPs in the bowel of DSS-treated mice (Figure 5C). 
These data demonstrated the capability of MAdCAM-1 targeting to promote the selective accumulation of 
nanoparticles at the inflamed colon. Interestingly, MnO-MdC NPs preferentially localized in the proximal 
colon, hence indicating perfect correlation with MAdCAM-1, whose expression was confirmed high in the 
cecum of all mice (Figure 5E).  
TEM analysis on samples of proximal colon showed MnO-MdC NPs on the apical surface of the 
endothelium of venules at 24 h post-injection. Nanoparticles attached to the endothelium and triggered 
invagination of the plasma membrane, thus suggesting specific uptake by endothelium in the inflamed colon 
(Figure 6). 
 
Biodistribution and safety of nanoparticles 
Biodistribution of MnO-MdC NPs and MnO-IgG NPs was determined by analyzing fluorescence in 
dissected non-target organs. Nanoparticles did not show preferential accumulation in heart, spleen, lungs, 
kidneys or liver. A mild signal was only detected in liver and kidneys, likely suggesting a potential way of 
clearance (Table 2). Systemic toxicity was assessed by histopathological examination in selected organs 
isolated 24 h post-injection. No histological lesions were observed, thus demonstrating safety of intravenous 
administration of the nanoconjugates (Figure 7). 
 
!  
Discussion   
Mortality for acute severe colitis reaches up to 70% if urgent colectomy is not performed, and about one 
third of patients hospitalized for severe colitis require immediate colectomy [8, 33]. This dramatic 
conclusion could be the result of steroid refractory IBD. In this scenario, early recognition of worsening 
colitis could impact on decision-making, by a proper treatment escalation or prompt starting of rescue 
therapy [8]. However, only clinical signs or aspecific imaging features are currently used to define severity 
of acute colitis [9, 34]. A delayed recognition of therapy failure means a delayed colectomy, which is 
associated to higher complications in patients with refractory colitis [9]. Indeed, several therapies are 
currently available as a salvage treatment in patients affected by severe colitis. Therefore, clinicians are more 
prone to elongate rescue therapy attempts, and patients could be referred for colectomy only at later stages of 
the disease, when septic shock is ongoing and malnutrition is worsening. Operating such patients is unsafe, 
and it carries a higher risk of anastomotic leak, fistula, hemorrhage and need for ileostomy [35]. Therefore, a 
fast and accurate reassessment for early acute colitis should be mandatory to guarantee the best management 
of these patients, with a wise and timely treatment. 
In this scenario, nanomedicine offers novel solutions for theranostic purposes in various clinical settings. A 
wide literature exists about the translational potential of nanotechnology in cancer or infectious diseases, but 
the application to IBD management has been poorly investigated.[36] In this study, we developed a targeted 
nanoplatform for early recognition of acute colitis. Our findings demonstrated that MAdCAM-1-targeted 
nanoparticles actively accumulated in inflamed bowel sites due to MAdCAM-1 overexpression in 
endothelium. At 4 h post-injection, both targeted and untargeted nanoparticles reached the colon, probably 
due to the extensive inflammation infiltrate from the blood to the inflamed tissue in colitic mice. However, at 
24 h, a significant proportion of targeted nanoparticles accumulated in proximal colon, whereas untargeted 
nanoparticles were mostly washed out. Active targeting of the endothelium within the inflamed bowel was 
demonstrated by TEM images, and allowed us to identify the sites of bowel inflammation.  
The rationale in choosing MAdCAM-1 as target for nanoparticles homing resides in multiple advantages. 
First, MAdCAM-1 offers high and early correlation with the active bowel inflammation, as demonstrated by 
the concurrence between MAdCAM-1 expression profile and the histological assessment of active 
inflammation in colonic mucosa of DSS-treated mice. Targeting leukocyte traffic in inflamed bowel is 
currently considered a promising strategy for IBD treatment.[18,37] The GEMINI I and GEMINI II-III trials 
have demonstrated a substantial clinical benefit with a targeted antibody to α4β7 integrins in patients affected 
by ulcerative colitis and Crohn’s disease, even in case of previous anti-TNF treatment.[38-40] In 2015, the 
TURANDOT and OPERA trials focused on MAdCAM-1 as a natural ligand of α4β7 integrins.[41,42] 
Clinical remission was higher in ulcerative colitis and in patients not exposed to anti-TNF treatment, while 
patients with Crohn’s disease were unexpectedly less susceptible to this therapy.[39] These milestone trials 
indicated a partial success for anti-MAdCAM-1 therapy in IBD; however, they provided encouraging proof 
of concept that targeting leukocyte traffic may represent a tailored therapy for IBD. MAdCAM-1 targeting 
could be even more appealing when considering its correlation with both intestinal and extra-intestinal 
IBD.[43] In our study a certain amount of MnO-MdC NPs was detected in liver, kidneys and lungs. Indeed, 
lungs and liver can be involved in extra-intestinal inflammatory damage in DSS-induced acute colitis.[44,45] 
However, the presence of nanoparticles in these off-target districts could also be likely attributable to 
excretion pathways. 
Previous studies on anti-MAdCAM nanoparticle-based strategies for IBD are sporadic and mainly involved 
gas micro-bubbles to improve contrast-enhancement in bowel ultrasound.[46,47] These studies revealed an 
unexpected role for targeted nanomedicine in IBD; however, their translation into clinical practice could be 
limited by pitfalls of bowel ultrasound, which requires high expertise and should be restricted only in tertiary 
centers. 
The choice of MnO NPs is related to the low toxicity and to the paramagnetic properties of the core that 
provides a large exploitable nanoplatform. MnO NPs biocompatibility attested that MnO NPs are safe for 
cell culture even at high concentrations. For these reasons, MnO NPs could be very promising substitutes for 
the clinically used gadolinium ions as positive contrast enhancer for IBD imaging.[11] Manganese is 
expected to overcome major limitations encountered with gadolinium, mainly its toxicity, the narrow 
imaging window due to short blood circulation time and its drop in relaxivity under high magnetic fields.[48] 
As a consequence, manganese is potentially preferable for molecular and tissue MRI imaging in T1-
weighted, positive-contrast MRI.[48] Recently, Rimola et al. have pointed out the relevance of 
discriminating bowel wall thickening due to active inflammation from fibrotic stenosis.[49] This issue is 
even more challenging in patients that have been previously subjected to gastrointestinal surgery, where 
discriminating between active IBD, pathological fibrosis and anastomotic scars is arduous.[49] Accurate 
contrast enhancement of active IBD, by properly homing MnO to MAdCAM-1-overexpressing bowel sites, 
is expected to circumvent such limitations and avoid nonspecific enhancements. In view of the remarkable 
contrast power of MnO NPs in T1-weighted images, our results strongly suggest future in vivo MRI studies.   
Conclusions 
MAdCAM-1-targeted MnO nanoparticles are very promising tools for accurate and early detection and 
treatment of active IBD, even in early stages of disease, when damage is demonstrated only by 
histopathology. Clinical potential of such nanoconjugate is undeniable, considering the ability to 
discriminate active inflammation from fibro-stenosing alterations even in the post-surgical setting. Further 
studies by MRI are now mandatory, and could allow to get closer to clinical translation, and to explore 
therapeutic potentials of targeted nanomedicine in IBD. 
  
Summary!points!
• Evaluation and management of IBD commonly relies on aspecific signs of bowel inflammation and 
are currently lacking of early and accurate targeted imaging systems.  
• Development of smart MnO nanoparticles conjugated with anti-MAdCAM-1 antibodies for selective 
detection of active bowel inflammation foci. 
• MnO nanoparticles were safe and non-toxic in vitro and in vivo. 
• MAdCAM-1-targeted nanoparticles actively accumulated in inflamed bowel sites in murine model 
of acute colitis, due to MAdCAM-1 overexpression on gut endothelium. 
• MAdCAM-1-targeted MnO nanoparticles could be promising tools for accurate detection and 
treatment of active IBD.!
!
!
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Reference Annotation 
[4] This reference is of interest because it represents the latest updated guidelines by the European Crohn’s 
and Colitis Organization (ECCO) for classification, diagnosis and medical management of ulcerative colitis 
for IBD patients. 
[6] A survey at European level on the impact of IBD on patients’ quality of life was performed. Most 
patients claimed that IBD negatively affected their life; therefore it is crucial and urgent to develop 
efficacious and non-invasive systems able to promote a tailored therapy of IBD without providing additional 
distress to the patients. 
[14] This reference discussed the relevance of MAdCAM-1 protein in IBD pathogenesis and its association 
with anti-TNF therapies, thus supporting the hypothesis of our study that targeting MAdCAM-1 could be of 
success.  
[22] This review provides an extensive overview on the biomedical applications of magnetic nanoparticles, 
thus indicating how nanotechnology could promote novel concepts in medicine. 
[25] This paper demonstrated the potential of MnO NPs as contrast agent in MRI, and represented a 
reference for the synthesis of MnO-based nanoparticles used in our study.  
[49] This reference focused on the importance of discriminating bowel wall thickening due to active 
inflammation from fibrotic stenosis. In this perspective, our nanoconjugate is expected to implement the 
MRI diagnosis of the disease. 
!
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Table 1. DLS and TEM analyses of MnO and MnO-PMA NPs. 
 
 
Effective 
diameter (TEM 
analysis, nm) 
Hydrodinamic 
diameter (DLS 
analysis, nm) 
PdI -potential (mV) 
MnO NPs 9.8 ± 1.3 15.0 ± 0.3 0.148 ± 0.041 - 
MnO-PMA NPs 9.9 ± 1.3 41.1 ± 1.9 0.237 ± 0.052 –44.7 ± 0.6 
 ! !
Table 2. Averaged epifluorescence intensity of organs dissected at 4 or 24 h post-nanoparticles-injection. 
Data are expressed as mean radiant efficiency (p/sec/cm2/sr)/(µW/cm2). 
Organ MnO-MdC (× 108) MnO-IgG (× 108) 
 4 h 24 h 4 h 24 h 
Liver 0.124 ± 0.089 0.102 ± 0.054 0.002 ± 0.002 0.878 ± 0.034 
Kidneys 0.178 ± 0.098 0.114 ± 0.064 0.027 ± 0.027 0.348 ± 0.103 
Spleen n.d. n.d. n.d. n.d. 
Heart n.d. n.d. n.d. n.d. 
Lungs 0.106 ± 0.065 0.092 ± 0.103 0.042 ± 0.042 0.119 ± 0.048 
n.d. not-detectable !
  
Figure Legends 
Figure 1. TEM micrograph of MnO NPs. Scale bar: 100 nm. 
 
Figure 2.  In vitro cytotoxicity study of nanoparticles. (A) Cell viability was assessed by MTS assay upon 
treatment with MnO-PMA NPs. Mean absorbance of untreated cells (CTRL) was set at 100% viability. 
Reported values are means ± SE (n=6). (B) The percentage of apoptotic cells was determined at 4 and 24 h 
of incubation with MnO-PMA NPs and compared to untreated cells (CTRL). Results are means ± SE (n=3). 
(C) Hemolysis was assessed on blood samples upon incubation with increasing concentrations of MnO-MdC 
(left panel) or MnO-IgG (right panel) NPs for 30 min, 2 h and 24 h. Results are means ± SE (n=3). 
 
Figure 3. Changes over time in body weight (A), stool consistency (B), and fecal blood (C) were scored 
daily in control (water) and treated (DSS) mice. (D) Colitis severity was assessed by DAI. (E) Colon length 
of water-drinking and DSS-treated mice was measured ex vivo. Results are means ± SE (n=8). (F) HE of 
colon sections from control or DSS-treated mice (20× magnification). 
 
Figure 4. MAdCAM-1 expression in colitic bowels. (A) Western blotting of MAdCAM-1 in tissue 
homogenates of proximal (p) and distal (d) colon from control (water) and treated (DSS) mice. (B) 
Densitometry of MAdCAM-1 bands normalized to GAPDH. Data are means ± SE (n=4). Asterisks indicate 
significance of DSS-treated versus water-drinking mice; §P< 0.05 proximal versus distal colon. (C) 
Representative pictures of MAdCAM-1 immunohistochemistry in colon specimens from control (water) and 
DSS-treated mice (40× magnification). 
 
Figure 5. Bowel imaging upon nanoparticles exposure. (A) Colon length was measured in colitic mice 
injected with saline (CTRL) or with MnO-MdC or MnO-IgG NPs, and compared to healthy mice (water). 
Results are means ± SE. (B) Averaged epifluorescence (Epf) intensity of colon dissected 4 or 24 h post-
nanoparticles-injection. Results are means ± SE (n=5). **P<0.05 MnO-MdC versus MnO-IgG; §P<0.05 24 h 
versus 4 h. (C) Epf intensity of bowels was normalized toward the fluorescence intensity (FI) of plasma 
collected from the same animal at 24 h. Results are means ± SE (n=5). (D) Epf images of representative 
bowels from mice exposed to saline (CTRL), MnO-MdC or MnO-IgG NPs for 4 or 24 h. Epf is expressed as 
radiant efficiency (p/sec/cm2/sr)/(µW/cm2). White lines indicate ileum/colon boundary. (E) MAdCAM-1 
immunohistochemistry in cecum specimens: arrows point at MAdCAM-1-positive vessels, asterisks indicate 
tissue lesions (20× magnification). 
 
Figure 6. TEM images of proximal colon specimens from mice exposed to MnO-MdC NPs for 24 h. Arrows 
point at a nanoparticle adhering to the endothelium of mucosal venules (scale bar: 500 nm). Higher 
magnification is shown on the right (scale bar: 200 nm). 
 
Figure 7. Histopathological analysis of non-target organs at 24 h post-nanoparticles-injection (40× 
magnification).  
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